journal
MENU ▼
Read by QxMD icon Read
search

Lancet Neurology

journal
https://www.readbyqxmd.com/read/28647156/corrections
#1
(no author information available yet)
No abstract text is available yet for this article.
June 21, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28645854/deep-brain-stimulation-in-tourette-s-syndrome-new-insights
#2
David J Pedrosa, Lars Timmermann
No abstract text is available yet for this article.
June 20, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28645853/anterior-pallidal-deep-brain-stimulation-for-tourette-s-syndrome-a-randomised-double-blind-controlled-trial
#3
Marie-Laure Welter, Jean-Luc Houeto, Stéphane Thobois, Benoit Bataille, Marc Guenot, Yulia Worbe, Andreas Hartmann, Virginie Czernecki, Eric Bardinet, Jerome Yelnik, Sophie Tezenas du Montcel, Yves Agid, Marie Vidailhet, Philippe Cornu, Audrey Tanguy, Solène Ansquer, Nematollah Jaafari, Emmanuel Poulet, Giulia Serra, Pierre Burbaud, Emmanuel Cuny, Bruno Aouizerate, Pierre Pollak, Stephan Chabardes, Mircea Polosan, Michel Borg, Denys Fontaine, Bruno Giordana, Sylvie Raoul, Tiphaine Rouaud, Anne Sauvaget, Isabelle Jalenques, Carine Karachi, Luc Mallet
BACKGROUND: Deep brain stimulation (DBS) has been proposed to treat patients with severe Tourette's syndrome, and open-label trials and two small double-blind trials have tested DBS of the posterior and the anterior internal globus pallidus (aGPi). We aimed to specifically assess the efficacy of aGPi DBS for severe Tourette's syndrome. METHODS: In this randomised, double-blind, controlled trial, we recruited patients aged 18-60 years with severe and medically refractory Tourette's syndrome from eight hospitals specialised in movement disorders in France...
June 20, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28642125/safety-and-efficacy-of-dual-lead-thalamic-deep-brain-stimulation-for-patients-with-treatment-refractory-multiple-sclerosis-tremor-a-single-centre-randomised-single-blind-pilot-trial
#4
Seth F Oliveria, Ramon L Rodriguez, Dawn Bowers, Daniel Kantor, Justin D Hilliard, Erin H Monari, Bonnie M Scott, Michael S Okun, Kelly D Foote
BACKGROUND: Efficacy in previous studies of surgical treatments of refractory multiple sclerosis tremor using lesioning or deep brain stimulation (DBS) has been variable. The aim of this study was to investigate the safety and efficacy of dual-lead thalamic DBS (one targeting the ventralis intermedius-ventralis oralis posterior nucleus border [the VIM lead] and one targeting the ventralis oralis anterior-ventralis oralis posterior border [the VO lead]) for the treatment of multiple sclerosis tremor...
June 19, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28642124/identification-of-genetic-variants-associated-with-huntington-s-disease-progression-a-genome-wide-association-study
#5
Davina J Hensman Moss, Antonio F Pardiñas, Douglas Langbehn, Kitty Lo, Blair R Leavitt, Raymund Roos, Alexandra Durr, Simon Mead, Peter Holmans, Lesley Jones, Sarah J Tabrizi
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. METHODS: We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008-11)...
June 19, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28642123/multiple-sclerosis-tremor-are-technical-advances-enough
#6
Derrick Soh, Alfonso Fasano
No abstract text is available yet for this article.
June 19, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28642122/identifying-modifiers-of-huntington-s-disease-progression
#7
Carsten Saft
No abstract text is available yet for this article.
June 19, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28629880/a-new-tool-to-identify-patients-with-parkinson-s-disease-at-increased-risk-of-dementia
#8
Dag Aarsland, Byron Creese, K Ray Chaudhuri
No abstract text is available yet for this article.
June 16, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28629879/prediction-of-cognition-in-parkinson-s-disease-with-a-clinical-genetic-score-a-longitudinal-analysis-of-nine-cohorts
#9
Ganqiang Liu, Joseph J Locascio, Jean-Christophe Corvol, Brendon Boot, Zhixiang Liao, Kara Page, Daly Franco, Kyle Burke, Iris E Jansen, Ana Trisini-Lipsanopoulos, Sophie Winder-Rhodes, Caroline M Tanner, Anthony E Lang, Shirley Eberly, Alexis Elbaz, Alexis Brice, Graziella Mangone, Bernard Ravina, Ira Shoulson, Florence Cormier-Dequaire, Peter Heutink, Jacobus J van Hilten, Roger A Barker, Caroline H Williams-Gray, Johan Marinus, Clemens R Scherzer
BACKGROUND: Cognitive decline is a debilitating manifestation of disease progression in Parkinson's disease. We aimed to develop a clinical-genetic score to predict global cognitive impairment in patients with the disease. METHODS: In this longitudinal analysis, we built a prediction algorithm for global cognitive impairment (defined as Mini Mental State Examination [MMSE] ≤25) using data from nine cohorts of patients with Parkinson's disease from North America and Europe assessed between 1986 and 2016...
June 16, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28601474/potential-biomarker-breakthrough-for-huntington-s-disease
#10
Christopher A Ross, Jee Bang
No abstract text is available yet for this article.
June 7, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28601473/neurofilament-light-protein-in-blood-as-a-potential-biomarker-of-neurodegeneration-in-huntington-s-disease-a-retrospective-cohort-analysis
#11
Lauren M Byrne, Filipe B Rodrigues, Kaj Blennow, Alexandra Durr, Blair R Leavitt, Raymund A C Roos, Rachael I Scahill, Sarah J Tabrizi, Henrik Zetterberg, Douglas Langbehn, Edward J Wild
BACKGROUND: Blood biomarkers of neuronal damage could facilitate clinical management of and therapeutic development for Huntington's disease. We investigated whether neurofilament light protein NfL (also known as NF-L) in blood is a potential prognostic marker of neurodegeneration in patients with Huntington's disease. METHODS: We did a retrospective analysis of healthy controls and carriers of CAG expansion mutations in HTT participating in the 3-year international TRACK-HD study...
June 7, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28600189/effect-of-high-dose-simvastatin-on-cognitive-neuropsychiatric-and-health-related-quality-of-life-measures-in-secondary-progressive-multiple-sclerosis-secondary-analyses-from-the-ms-stat-randomised-placebo-controlled-trial
#12
Dennis Chan, Sophie Binks, Jennifer M Nicholas, Chris Frost, M Jorge Cardoso, Sebastien Ourselin, David Wilkie, Richard Nicholas, Jeremy Chataway
BACKGROUND: In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures. METHODS: We did a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS done at three neuroscience centres in the UK between Jan 28, 2008, and Nov 4, 2011...
June 6, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28600188/simvastatin-and-cognition-in-multiple-sclerosis
#13
Massimo Filippi, Maria A Rocca
No abstract text is available yet for this article.
June 6, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28566190/the-promise-of-telemedicine-for-chronic-neurological-disorders-the-example-of-parkinson-s-disease
#14
REVIEW
Ruth B Schneider, Kevin M Biglan
Disparities in access to health care, particularly specialist care, exist worldwide. As the prevalence of chronic neurological disorders increases with ageing populations, access to neurologist care is likely to worsen in many regions if there are no changes to models of care. Telemedicine-defined here as the use of real-time, synchronous videoconferencing to deliver medical care-could be used to improve access to neurologist care for patients with a range of chronic neurological disorders. In Parkinson's disease, several studies have shown the feasibility and potential benefits of telemedicine-delivered care...
May 26, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28522181/safety-and-efficacy-of-edaravone-in-well-defined-patients-with-amyotrophic-lateral-sclerosis-a-randomised-double-blind-placebo-controlled-trial
#15
(no author information available yet)
BACKGROUND: In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect than did the full study population...
May 15, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28522180/edaravone-a-new-treatment-for-als-on-the-horizon
#16
Orla Hardiman, Leonard H van den Berg
No abstract text is available yet for this article.
May 15, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28499853/epilepsy-and-two-evolving-societies
#17
Adrian Burton
No abstract text is available yet for this article.
May 9, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28499852/withdrawal-of-antiepileptic-drugs-an-individualised-approach
#18
Jacqueline A French
No abstract text is available yet for this article.
May 9, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28483337/individualised-prediction-model-of-seizure-recurrence-and-long-term-outcomes-after-withdrawal-of-antiepileptic-drugs-in-seizure-free-patients-a-systematic-review-and-individual-participant-data-meta-analysis
#19
Herm J Lamberink, Willem M Otte, Ada T Geerts, Milen Pavlovic, Julio Ramos-Lizana, Anthony G Marson, Jan Overweg, Letícia Sauma, Luigi M Specchio, Michael Tennison, Tania M O Cardoso, Shlomo Shinnar, Dieter Schmidt, Karin Geleijns, Kees P J Braun
BACKGROUND: People with epilepsy who became seizure-free while taking antiepileptic drugs might consider discontinuing their medication, with the possibility of increased quality of life because of the elimination of adverse events. The risk with this action, however, is seizure recurrence. The objectives of our study were to identify predictors of seizure recurrence and long-term seizure outcomes and to produce nomograms for estimation of individualised outcomes. METHODS: We did a systematic review and meta-analysis, and identified eligible articles and candidate predictors, using PubMed and Embase databases with a last update on Nov 6, 2014...
May 5, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28460892/safety-and-efficacy-of-erenumab-for-preventive-treatment-of-chronic-migraine-a-randomised-double-blind-placebo-controlled-phase-2-trial
#20
Stewart Tepper, Messoud Ashina, Uwe Reuter, Jan L Brandes, David Doležil, Stephen Silberstein, Paul Winner, Dean Leonardi, Daniel Mikol, Robert Lenz
BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is important in migraine pathophysiology. We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine. METHODS: This was a phase 2, randomised, double-blind, placebo-controlled, multicentre study of erenumab for adults aged 18-65 years with chronic migraine, enrolled from 69 headache and clinical research centres in North America and Europe...
April 28, 2017: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"